

ITALIAN SUMMIT on PRECISION MEDICINE



Presidents: *Giuseppe Curigliano, Paolo Marchetti*

Rome, 14th - 15th April 2025 - Villa Aurelia - Largo Porta San Pancrazio, 2

Fmp
Fondazione per la
Medicina Personalizzata

ITALIAN SUMMIT **on** PRECISION MEDICINE

Presidents: *Giuseppe Curigliano, Paolo Marchetti*

The Baths of Caracalla, also known as the Antoninianae Baths (Thermae Antoninianae in Latin, named after Emperor Caracalla of the Severan dynasty), stand as one of Rome's most remarkable preserved imperial bath complexes, still preserving much of their structure and free from modern buildings. Constructed on the Small Aventine Hill between AD 212–216 (as evidenced by brick stamps), this monumental site lies adjacent to the Appian Way's initial stretch, approximately 400 meters beyond the ancient Porta Capena and just south of the sacred Camene Grove. After 1,500 years, water resumed flowing through its newly installed reflecting pool at the monument's entrance in 2024.

Rome, 14th - 15th April 2025 - Villa Aurelia - Largo Porta San Pancrazio, 2

Rational

Personalizing cancer medicine depends on the implementation of personalized diagnostics and therapeutics. Detailed genomic screening is likely to play a central role in this.

Personalized Medicine has been widely depicted as a striking innovation, that is able to reform the standard approach to disease management, replacing the one-size-fits-all scheme of medicine with a single-patient-sized medical intervention. Personalized medicine promoters usually highlight its potential to combine a more effective healthcare with cost containment, according to the following rules:

- monitoring of disease risks and more effective prevention;
- early intervention;
- selection of optimal therapy;
- reduction of trial-and-error prescribing and reduction of adverse drug reactions;
- exclusion of unnecessary drugs;
- therapeutic drug monitoring and disease progression/remission monitoring;
- increased patient compliance with therapy.

But, in spite of expectations, many unsolved practical issues, from technical and scientific to ethical, legal and economic topics, are slowing down the translation of personalized medicine principles into medical practice. Furthermore, wide adoption of personalized strategies also has to deal with the peculiar rules, policy and reimbursement system of each country. Application of Personalized Medicine in the real world seems entangled by the unmet need to develop evidence-based guidelines.

The aim of the meeting, where we are expecting about 150/200 participants from Italy and Europe, is to discuss with principal key opinion leaders about the future prospects of precision medicine and precision oncology and the application in the real world.

Programme

14th April 2025

13:00 - 13:30 Welcome reception

13:30 - 13:45 **Opening and welcome**
Giuseppe Curigliano, Paolo Marchetti

13:45 - 14:15 **Keynote 1**
Classifying cancers according to their molecular characteristics
Antoine Italiano

14:15 - 14:45 **Lecture**
The future of drug development
Giampaolo Tortora

14:45 - 16:15 **Educational session 1:** liquid biopsy for cancer precision medicine
Chair: Pedram Razavi
Novel methodologies for ultradeep assessment of ctDNA
Pedram Razavi

New frontiers for the use of circulating tumor cells in precision medicine
Eleonora Nicolò
ctDNA applications in clinical practice
Edoardo Crimini

Q&A

16:15 - 16:30 Coffee break

16:30 - 18:00 **Educational session 2:** novel avenues for antibody drug conjugates development

Chairs: *Giuseppe Curigliano, Funda Meric-Bernstam*

Biomarkers of response and resistance to antibody drug conjugates

Sarat Chandarlapaty

Combining ADCs with targeted therapies and immunotherapy

Timothy A. Yap

Optimizing the safety of antibody drug conjugates for the treatment of cancer

Simone Scagnoli

Novel antibody drug conjugates and beyond

Funda Meric-Bernstam

Q&A

18:00 - 18:30 **Keynote 2**

Introduction

Giuseppe Curigliano

Shaping precision oncology's future: a scientific journal's perspective on cancer innovation

Ulrike Harjes

15th April 2025

8:40 - 9:00 **Keynote 3**

Introduction

Paolo Marchetti

Assessment of minimal residual disease in solid tumors

Alberto Bardelli

9:00 - 10:30 **Educational session 3:** artificial Intelligence for cancer precision medicine

Chairs: *Jakob Kather, Nello Martini*

Artificial intelligence for biomarker assessment in cancer

Jakob Kather

Multimodal data integration to advance precision oncology

Jeffrey Ross

Design of next generation precision medicine trials using artificial intelligence

Vivek Subbiah

Use of artificial intelligence in clinical practice: is it ready for prime time?

Antonio Marra

Q&A

10:30 - 10:45 Coffee break

10:45 - 12:10 **Educational session 4** updates on tumor-specific targeted treatments

Chairs: *Giuseppe Tonini, Giampaolo Tortora*

Gastrointestinal cancers

Chiara Cremolini

Breast cancer

Paola Zagami

Genitourinary cancers

Giuseppe Procopio

Lung cancers

Emilio Bria

Head and neck and rare tumors

Alessio Cirillo

Q&A

General Information

- 12:15 - 13:15** Satellite symposium (not-ECM accredited)
“IDH mutations: actionable oncogenic drivers across cancers”
Chairs: *Giuseppe Curigliano, Paolo Marchetti*
- 13:15 - 14:10** Lunch
- 14:10 - 14:40** **Keynote 4**
Introduction
Giuseppe Curigliano
Novel frontiers in early drug development
Funda Meric Bernstam
- 14:45 - 16:15** **Educational session 5:** building a framework for precision medicine
Chairs: *Paolo Marchetti, Ruggero De Maria*
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers
Benedikt Westphalen
Recommendations on clinical reporting of genomics test results
Giancarlo Pruneri
Molecular Tumor Boards and beyond
Luca Boscolo Bielo
Global accessibility to new drugs in oncology
Dario Trapani
Q&A
- 16:15 - 16:30** Conclusions
- 16:30 - 16:45** Final evaluation test

Presidents: ***Giuseppe Curigliano, Paolo Marchetti***
Congress Venue: Villa Aurelia - Largo di Porta San Pancrazio, 2 - Rome
CME Provider n. 4795
Didactika S.r.l. Piazza della Trasfigurazione, 8/a - 00151 Rome
ref. n. 436569
CME Credits: 9,1
This event is open to biologists, medical doctors, surgeons, and psychologists.

Disciplines:

Dermatology and Venereology; Hematology; Medical Genetics; Internal Medicine; Oncology; Radiotherapy; General Surgery; Maxillofacial Surgery; Plastic and Reconstructive Surgery; Thoracic Surgery; Gynecology and Obstetrics; Urology; Pathological Anatomy; Clinical Biochemistry; Pharmacology and Clinical Toxicology; Clinical Pathology (Clinical Chemical Analysis Laboratory and Microbiology); Radiology; General Medicine (Family Practitioners); Palliative Care; Epidemiology;

To obtain the CME credits, the participant should be present for at least 80% of the total duration of the Congress, fill in all the forms and pass the final CME test. At the end of the Congress, the organizing secretariat will issue a certificate of attendance.

Registration:

Registration is free and necessary. To register for the Congress, please visit us at www.didactika.it or send the registration form by e-mail to: info@didactika.it

Registration includes:

Access to all scientific sessions. Certificate of attendance.

This congress will be held in presence for a maximum of 150 participants.

Speakers and Chairmen

Alberto Bardelli: IFOM ETS, Dept. Of Oncology, University of Turin (Italy)

Luca Boscolo Bielo: Dept. of Experimental Oncology, European Institute of Oncology, IEO-IRCCS Milan (Italy)

Emilio Bria: Fondazione Policlinico Universitario Agostino Gemelli - IRCCS, Comprehensive Cancer Center, Rome (Italy)

Sarat Chandarlapaty: Memorial Sloan Kettering Cancer Center, New York (USA)

Alessio Cirillo: Dept. of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I, Sapienza University of Rome (Italy)

Chiara Cremolini: Medical Oncology at University of Pisa and Azienda Ospedaliero-Universitaria Pisana, Pisa (Italy)

Edoardo Crimini: Department of Experimental Oncology, European Institute of Oncology, IEO-IRCCS Milan (Italy)

Giuseppe Curigliano: Dept. of Oncology and Hemato-Oncology, University of Milan, European Institute of Oncology, IEO-IRCCS Milan (Italy)

Ruggero De Maria Marchiano: Institute of General Pathology, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS, Comprehensive Cancer Center Rome; Alliance Against Cancer ACC, Rome (Italy)

Ulrike Harjes: Senior Editor Nature Medicine, Berlin (Germany)

Antoine Italiano: Early Phase Trials and Sarcoma Units, Department of Medicine, Institut Bergonié, Bordeaux (France)

Jakob Kather: Clinical Artificial Intelligence at Technical University (TU), Dresden (Germany)

Paolo Marchetti: Istituto Dermopatico dell'Immacolata, IDI-IRCCS Rome (Italy)

Antonio Marra: Division of Early Drug Development for Innovative Therapies European Institute of Oncology, IEO-IRCCS Milan (Italy)

Funda Meric-Bernstam: Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, MD Anderson Cancer Center, Houston (USA)

Nello Martini: Ricerca e Salute Foundation, Rome (Italy)

Eleonora Nicolò: Dept.of Medicine Weill Cornell University, New York (USA)

Giuseppe Procopio: Department of Medical Oncology at the National Cancer Institute, INT-IRCCS Milan, (Italy)

Giancarlo Pruneri: National Cancer Institute, INT-IRCCS and School of Medicine University of Milan, (Italy)

Pedram Razavi: Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York (USA)

Jeffrey Ross: Foundation Medicine; Departments of Pathology and Urology, Upstate Medical University, Syracuse (USA)

Simone Scagnoli: Dept. of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I, Sapienza University of Rome (Italy)

Vivek Subbiah: Early-Phase Drug Development at Sarah Cannon Research Institute, Nashville (USA)

Timothy A. Yap: Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston-Texas (USA)

Dario Trapani: Dept. of Oncology and Hemato-Oncology, University of Milan, European Institute of Oncology, IEO-IRCCS Milan (Italy)

Christoph Benedikt Westphalen: Medical Oncology Dept., LMU Klinikum der Universität, Munich (Germany)

Paola Zagami: Dept. of Oncology and Hemato-Oncology, University of Milan, European Institute of Oncology, IEO-IRCCS Milan (Italy)

Thanks to the non conditioning contribution of:

SERVIER
moved by you

Pfizer
Oncology

Roche

Lilly
A MEDICINE COMPANY

NOVARTIS

Daiichi-Sankyo

AstraZeneca

MSD

accord
We make it better

illumina

Incyte

MENARINI Stemline

AMGEN

Provider
DK
Didactika srl

eton
Ne.T.On. S.r.l.